Meet the Chinese Investors
Join us for an exclusive opportunity to meet some Chinese investors looking to invest in British Biotechs. We will hear from key Chinese investors located here in the UK, but with China based funds. There will be a chance for one-to-one meetings with the investors you think most relevant to your company.
This is an invitation only event for bioscience companies.
Investors confirmed so far:
Tuspark UK hopes to discuss investment opportunities with businesses from different perspectives that can collaborate with our portfolio companies in China, including biotech, medtech, pharmaceutical, and medical devices. Interested companies should have survived their infant stage, or at least been awarded with commercial contracts, and have an ambition to develop their business in China.
Zhuocun (Kevin) Lin, currently President and representative of Tuspark in the UK, graduated with a Master’s degree in Public Administration from Tsinghua University. He used to work in financial sector in China for more than ten years, and accumulate deep understanding of Chinese financial system and regulations. He joined Tus S&T Service Group in 2016, the leading industrial investor in Science and Technology, as Vice-President in charge of international investment and collaborations. He is now leading the investment into UK and Europe, in fields of Biotech, life science, new energy, new materials, AI and high-end manufacture, mostly technology related.
Dr Huaizheng Peng
A former global investor and investment banker specialising in life science, biotechnology and pharmaceuticals, Dr Huaizheng Peng is a General Manager of China Medical System Holdings (CMS), International Operations. CMS is a publicly traded (HK: 0867) specialty pharmaceutical company with a market cap of multi-billion USD. Our business is driven by global innovations in life sciences and focusing on sale and marketing in China. He is responsible for firm’s international operations and global corporate development, including pharmaceutical asset acquisition/ product licencing-in/out, international business development, and asset management. In addition, he is a CEO of CMS Medical Venture, a corporate venture capital fund, and CEO of A&B fund, an investment vehicle of a family office. Both funds are strategically investing in the product-orientated companies on the global basis.
Prior to his pharmaceutical and financial industry career, he practiced medicine as a clinical lecturer in UCL Medical School, UK, after he received his Bachelor’s and Master’s degrees in Medicine from Hunan Medical College, PR China and his Doctoral of Philosophy in University of London, UK.
Oriza Seed Fund's primary focus is early stage innovative biotechs and medtechs. High-technology-component product oriented, provide motivating equity structure to founding team and hands-on
support where needed, constant risk balancing by sector/portfolio composition, leverage the domestic market and our existing ecosystem including but limited to portfolio companies
Yanchun Xia is a venture partner at Oriza Seed. Held management position in HSBC USA, participated in the establishment of Honda Bank Europe and Peugeot Bank China, was head of new product development with Société Général Corporate & Investment Banking at the headquarter for Global Finance Dpt. (primary and secondary market derivatives and structured finance), operated chronic disease management and hospital at home program, invested in medtech and participated in related MBO.
15.00 Registration and networking
15.35 Introductions and explainers from investors
15.50 1-to-1 meetings with investors – 5 minute meetings each
17.30 Further networking and drinks
65 Gresham Street